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Background: Mitogen-activated protein kinase-activated protein kinase 5 (MK5) is
involved in one of the major signaling pathways in cells, the mitogen-activated
protein kinase pathway. MK5 was discovered in 1998 by the groups of Houng Ni
and Ligou New, and was found to be highly conserved throughout the vertebrates.
Studies, both in vivo and in vitro, have shown that it is implicated in tumor
suppression as well as tumor promotion, embryogenesis, anxiety, locomotion,
cell motility and cell cycle regulation.
Methods: In order to obtain a molecular model of MK5 that can be used as a
working tool for development of chemical probes, three MK5 models were
constructed and refined based on three different known crystal structures of the
closely related MKs; MK2 [PDB: 2OZA and PDB: 3M2W] and MK3 [PDB: 3FHR]. The
main purpose of the present MK5 molecular modeling study was to identify the best
suited template for making a MK5 model. The ability of the generated models to
effectively discriminate between known inhibitors and decoys was analyzed using
receiver operating characteristic (ROC) curves.
Results: According to the ROC curve analyzes, the refined model based on 3FHR
was most effective in discrimination between known inhibitors and decoys.
Conclusions: The 3FHR-based MK5 model may serve as a working tool for
development of chemical probes using computer aided drug design. The biological
function of MK5 still remains elusive, but its role as a possible drug target may be
elucidated in the near future.
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Molecular dynamicsBackground
Mitogen-activated protein kinases (MAPKs) constitute a major signaling pathway in cells,
and are involved in processes controlling gene expression, cell division, cell survival,
apoptosis, metabolism, differentiation and motility [1]. The conventional mammalian
pathway consists of a cascade of three serine/threonine kinases referred to as MAPK
kinase kinase, MAPK kinase and MAPK. The MAPKs are divided into four different
subfamilies; the extracellular signal-regulated kinases 1/2 (ERK1/2), the c-JUN N-terminal
kinases 1–3 (JNK1-3) or stress-activated protein kinases (SAPKα, β and γ), the p38© 2013 Lindin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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way is not organized in the normal three tier cascade, and includes ERK3/4, ERK7/8
and Nemo-like kinase (NLK) [1]. Both the conventional and the unconventional pathway
can phosphorylate protein substrates and other protein kinases called mitogen-activated
protein kinase-activated protein kinases (MAPKAPK). The MAPKAPK family compro-
mises 11 Ser/Thr kinases and according to sequence similarities they can be subdivided
into four groups: ribosomal S6 kinases (RSK1-4), mitogen and stress activated kinases
(MSK1 and 2), MAPK-interacting kinases (MNK1 and 2) and MKs. The latter includes
the members MK2, MK3, and MK5 [2].
The present study focuses on mitogen-activated protein kinase-activated protein
kinase 5 (MK5). No analog to the mapkapk-5 gene seems to be present in invertebrates
or plants, but the vertebrate MK5 protein is a highly conserved protein kinase within
vertebrates sharing 87 to 99% amino acid identity with the human MK5. Its molecular
weight is 54,220 Da, and it is believed to be activated by both the conventional and
unconventional MAPK pathways [3]. MK5 was originally discovered in 1998 by the
research group of Houng Ni, as a novel murine kinase that could be phosphorylated
and activated by ERK and p38 but not by Jun N-terminal kinase (JNKs) in vitro [4]. Later
the research group of Ligou New also described a protein kinase activated downstream
of p38 MAP kinase and called it PRAK. This was the human analog of MK5 [5].
MK5/PRAK shares 42% overall amino acid identity with MK2 (with a 48% similarity
in the catalytic domain) and for MK5/MK3 the overall amino acid identity is 41%.
The sequence identity between MK2 and MK3 is 75% [2]. MK5 has been found to be
ubiquitously expressed throughout the human body, but has a predominant expression
in the heart, skeletal muscle, pancreas and lung [4-7]. In resting cells the protein
resides predominantly in the nucleus but is able to shuttle between the nucleus and
the cytoplasm. Nucleocytoplasmic shuttling is controlled through MK5s interaction
with PKA, Cdc15A and the upstream kinases ERK3/4 and p38 [8-16]. The in vivo
interaction between p38 and MK5 is, however, under some debate, and is currently
not completely resolved (reviewed in [17]).
A lot of experimental work has been performed to elucidate the biological role of
MK5. Studies by Tak and coworkers [18], Moens and coworkers [12,16,19], and Choi
and co-workers [20] have established the relationship between MK5, hTid-1 and
Hsp27 in F-actin rearrangement and cell migration. Several studies have shown the
importance of MK5 in cell cycling and proliferation. PRAK was reported to suppress
oncogenic RAS-induced proliferation [21], while overexpression of MK5 inhibited
proliferation of NIH3T3 cells [22]. MK5 was also found to be essential for ras-induced
senescence and thereby to act as a tumor suppressor [23]. Later it was also discovered
that MK5 may act as a tumor suppressor through downregulation of Myc [24]. MK5
may also be involved in inhibition of cell proliferation through ERK3 interaction
[25,26]. Moreover, MK5 may repress cell invasiveness [27]. Recent studies demon-
strated that MK5 can act as a tumor promoter [28]. The authors reported that MK5
stimulates angiogenesis [29]. The same group also unveiled a role of MK5 in cell
growth arrest induced by energy starvation [30]. Furthermore, animal studies have
suggested that MK5 is involved in neurological processes controlling anxiety and
locomotion [31]. Despite all these described functions the exact biological role of
MK5 still remains elusive.
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probes to help elucidate the role of MK5. In the present study, we have constructed
and refined three MK5 homology models based on three different templates; MK2
([PDB: 2OZA] and [PDB: 3M2W]) and MK3 [PDB: 3FHR]. The ability of the refined
models to effectively discriminate between known inhibitors and decoys was analyzed
using receiver operating characteristic (ROC) curves.Methods
Alignment
Sequence alignments of MK5/MK2 ([PDB: 2OZA] and [PDB: 3M2W]) and MK5/MK3
([PDB: 3FHR]), respectively, were constructed using ICM’s inbuilt alignment tool. These
alignments were adjusted manually to match multiple sequence alignment of the same
kinases. The multiple sequence alignment of human [Swiss-Prot: Q8IW41], mouse
[O54992], pig [B7U6F1], frog [Q6DEV6] and zebrafish [Q6DHN7] MK5, and human
[P49137], mouse [P49138], rat [Q80ZF4], hamster [P49136] and frog [Q28FG8] MK2, or
human [Q16644], mouse [Q3UMW7], pig [B8XSJ7], rat [Q66H84] and bovine [Q3SYZ2]
MK3 was obtained using T-coffee, Version 4.71 available at the Le Centre National
de la Recherche Scientifique website (www.igs.cnrs-mrs.fr/Tcoffee/tcoffee_cgi/index.cgi)
[32,33]. Finally adjusted alignments (Figures 1A, B and C) were used further for homology
modeling.Homology modeling
The amino acid sequence of human MK5 (Swiss-Prot: Q8IW41) was retrieved from the
Protein Knowledgebase of UniProt (www.uniprot.org) [34]. Close homologues with
available crystal structures in the Protein Databank (www.pdb.org) [35] were identified
using BLAST [36] through UniProt. The crystal structure of MK3 in complex with
pharmaceutical lead compound P40 [PDB: 3FHR], with a resolution of 1.90Å, and the
crystal structure of MK2 complexed with a spiroazetidine-tetracyclic ATP site inhibitor
[PDB: 3M2W] with a resolution of 2.4Å, had the highest resolutions of the available
MK2 and MK3 crystal structures and were identified as the most suitable template
candidates for homology modeling. In addition, the crystal structure of MK2 in complex
with p38 [PDB: 2OZA], with a 2.7Å resolution, which was used previously as a template
for the construction of an MK5 model [37], was also used as template to construct an
MK5 model for comparison. Thus, three MK5 models were constructed based on three
different templates; MK2 ([PDB: 2OZA] and [PDB: 3M2W]) and MK3 [PDB: 3FHR].
The homology macro of ICM [38] constructs the backbone of the target molecule by
homology from core sections of the template molecule. Core sections are defined by
the average of Cα atom positions in these regions, and side chain torsion angles are
then predicted by simultaneous global optimization of the energy for all non-identical
residues. Loops are subsequently searched for among several thousand structures in the
PDB data bank [35] and matched in regard to sequence similarity and steric interaction
with the surroundings of the model. Best fitting loops were selected by calculating
maps around loops and scoring their relative energies. The C-terminal part, which




Figure 1 Alignments. A: Final alignment used to create homology model of MK5 from MK3 [PDB: 3FHR].
See text for further description on how alignment was obtained. B: Final alignment used to create
homology model of MK5 from MK2 [PDB: 2OZA]. C: Final alignment used to create homology model of
MK5 from MK2 [PDB: 3M2W].
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was the ATP binding site, and the C-terminal part is not adjacent to the binding site.
The MK5 models were refined using the RefineModel macro of ICM which globally
optimizes side chains and anneals the backbone. The macro includes: (1) Monte Carlo fast
[39] simulation for sampling of the conformational space of side chains, (2) iterative
annealing of the backbone with tethers, which are harmonic restraints pulling an atom in
the model to a static point in space represented by a corresponding atom in the template,
and (3) a second Monte Carlo fast simulation on side chains. The Monte Carlo
method is a complete search of the conformational space of a protein or part of a
protein, and at each stage the actual conformation is modified randomly in order to
obtain a new one. Each iteration samples the conformational space of a molecule with
the ICM global optimization procedure, and consists of a random move followed by a
local energy minimization, and then a complete energy calculation. Based on the energy
and the temperature, the iteration is accepted or rejected [39].
The electrostatic potential surfaces (EPS) of the 3FHR-based MK5 model, the 3FHR
MK3 crystal structure and the 3M2W MK2 crystal structure were calculated with the
ICM program, with a potential scale from −5 to +5 kcal/mol using the ICM-REBEL
module of the ICM program. This module solves the Poisson equation for a molecule using
a boundary element algorithm and generates a 3D surface skin model colored by potential.Quality assessment of model/model validation
The SAVS Metaserver for analyzing and validating protein structures (http://nihserver.
mbi.ucla.edu/SAVS/) was used to check the stereo chemical quality of the MK5 models.
Programs run were ProCheck [40], What_Check [41], and Errat [42]. ProCheck checks
stereo chemical quality of the protein structure by analyzing residue-by-residue geometry
and overall structure geometry, while What_Check performs extensive checking of
many stereo chemical parameters of the residues in the model based on a subset of
protein verification tools from the WHAT IF program [43]. Errat analyzes the statistics of
non-bonded interactions between different atom types and plots the value of the error
function versus position of a 9-residue sliding window, calculated by a comparison with
statistics from highly refined structures.
Also the overall 3D structure of the models were checked against their templates,
and the RMSD values were calculated utilizing DaliLite (www.ebi.ac.uk/Tools/structure/
dalilite) [44].Inhibitors and decoys
ChEMBL (http://www.ebi.ac.uk/chembl/) was searched for putative MK5 inhibitors,
and 316 different compounds with varying ability to inhibit MK5 were identified.
Ten of the 316 inhibitors were selected based on known IC50 value (see Table 1) and
used as templates to identify decoy substances.
Decoys were retrieved using the Molcart chemical management system of ICM.
Molcart features a number of compound databases (including Ambinter, Chembrigde,
Lifechemicals, etc.) that can be analyzed and searched using ICM cheminformatic tools.
The decoys were selected based on structural similarities with the known inhibitors.
Similarities in molecular mass and in the number of nitrogen- and oxygen atoms were
Table 1 Putative MK5 inhibitors selected on basis of their IC50 value
Structure Chemical comp. ChEMBL comp id. Pubmed id. IC50 (nM)
C21H18N4OS CHEMBL1231206 20237073 5
C24H23N5O2 CHEMBL461139 18945615 24
C23H23N5O2 CHEMBL461140 18945615 28
C21H16N4O CHEMBL226403 17480064 81
C18H15N3O CHEMBL388566 17480064 140
C18H14FN3O CHEMBL226471 17480064 210
C12H11N3O CHEMBL225519 17480064 500
C30H28O8 CHEMBL34241 10998351 1900
C13H14N2O3 CHEMBL395157 17570666 19000
C18H16N6S2 CHEMBL34704 10998351 50000
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Ninety decoy substances evenly distributed between the different clusters were chosen
and used for docking studies in addition to the ten potential inhibitors (for full list of
decoys and inhibitors see Additional file 1). Decoys were chosen from different clusters
in order to get as diverse sample as possible.Identification of ligand binding pocket
The icmPocketFinder macro of ICM (default tolerance level at 4.6) was used to iden-
tify possible binding pockets in the models. The icmPocketFinder algorithm uses a
transformation of the Lennard-Jones potential calculated from a three-dimensional
protein structure and identifies envelopes according to their shape and physicochemical
properties [45]. The algorithm does not require any knowledge about the ligand, and
the pockets are based solely on the protein structure. The pocket selected for the
docking studies, localized in the ATP binding site of the templates, was identified by
icmPocketFinder.Docking
In the present study, semi-flexible docking, which keeps the protein itself rigid while the
ligand is flexible, was performed. ICM uses a Monte Carlo global optimization procedure
[39] to predict binding poses for the ligand in the binding pocket. 2D structures of inhibi-
tors and decoys structures were converted to 3D structures by ICM and automatically
assigned charges where necessary. The compounds were then docked into the predicted
ATP binding pocket of the different models using the batch docking method of ICM.
Three parallel docking runs were performed with each docking procedure and the best
score values of the three were kept for evaluation (See Additional files 2, 3, 4).Evaluation of docking
The overall predictability of the models was evaluated by ROC curves [46,47]. Inhibitors
are labeled 1 (as true inhibitors) and decoys are labeled 0 (as false inhibitors). Score values
are then analyzed using the ROC curve script incorporated into ICM. Results are
displayed as ROC curves, and the area under curve (AUC) is calculated. A straight
line ROC curve would signify that the model gives no preference to true inhibitors
over decoys or vice versa. A curve bowing more to the left indicates a greater accuracy
of the model (a higher ratio of true positives to false positives).Molecular dynamics
In order to refine protein-ligand interactions and to test the stability of the docking
pose of the best scored complex from the docking study, a molecular dynamics (MD)
simulation was run on the 3FHR-based MK5 model in complex with Ligand 92. The
binary complex was first optimized with protein preparation wizard in Maestro V9.1
[48] by assigning bond orders, adding hydrogen and correcting wrong bond types. The
system was neutralized by adding 8 Cl- ions. The simulated system consisted of a total of
77439 atoms. A default quick relaxation protocol was used to minimize the MD systems
with the Desmond program. In Desmond, the volume of space in which the simulation
take place (the global cell) is built up by regular 3D simulation boxes of 10Å X 10Å X
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and solvent was of approximately 90Å X 90Å X 90Å. In short, two rounds of steepest
descent minimization were performed with a maximum of 2000 steps with and without
restrains (force constant of 50 kcal/mol/Å on all solute atoms). This was followed by a
series of four MD simulations. The first simulation was run for 12 ps at a temperature of
10 K in the Berendsen NVT (constant number of particles, volume, and temperature)
ensemble with solute heavy atoms restrained (force constant of 50 kcal ⁄mol/Å). Next,
another 12 ps simulation was performed at 10 K with the same restraints, this time in the
Berendsen NPT (constant number of particles, pressure, and temperature) ensemble.
With the same restraint, a 12 ps simulation followed with the temperature raised to
300 K in the Berendsen NPT ensemble and the force constant retained. Finally, a 24 ps
simulation was performed at 300 K in the Berendsen NPT ensemble with all restraints
removed.
After these minimization steps, a total of 50 ns’ MD simulation was performed, using
the OPLS 2005 force field [49] at a constant pressure of 1 bar and a temperature of
300 K, using the Nose-Hoover chain [50] and Martyna-Tobias-Klein methods [51]. The
short-range and long-range Coulombic interactions were calculated with a cut off radius
of 9 Å and with the Smooth particle mesh [52] method (Ewald tolerance: 1e-9). Time step
scheduling was used as follows: the multistep RESPA integrator [53] with an inner time
step of 2.0 fs for bonded forces and non-bonded near forces within the short range cutoff,
an outer time step of 6.0 fs for non-bonded far forces beyond the cutoff.
Atomic distances important for ligand binding were calculated for the entire 50 ns
MD simulation. An average model was calculated from frames between 28.7 – 50 ns.
This average structure was first optimized by the protein preparation wizard in
Schrødinger to correct wrong bond types and overlapping atoms, and then minimized
using the Desmond Minimization program. The average model was solvated by a
10Å×10Å×10Å Orthorhombic SPC water box. Maximum number of iterations was
2000 and convergence threshold was 1.0 kcal/mol/Å. Steepest decent minimization was
performed until a gradient threshold of 25 kcal/mol/Å was reached, and followed by a
limited memory variation of the Broyden–Fletcher–Goldfarb–Shanno (LBFGS) method
with vectors 3. The short-range and long-range Coulombic interactions were the same
as for the MD simulation. No restraint was applied to the system.Results and Discussion
In the absence of an available X-ray crystal structure of MK5, we constructed MK5
homology models based on the structures of its close homologues MK2 (43% sequence
identity) and MK3 (41% sequence identity). Three different templates were used; [PDB:
2OZA [54]], [PDB: 3M2W [55]] and [PDB: 3FHR [56]]. The final models are presented
in Figures 2A-C. All predicted models have an N-terminal lobe consisting of a bundle
of β-sheets, a conserved α-helix and a conserved P-loop. The C-terminal lobe is largely
helical and contains the activation segment, including Thr182, which becomes phosphory-
lated when MK5 is activated. The hinge region connects the two lobes which locate
the presumable ATP binding site. The most striking differences between the models
are seen in the activation segment of the C-terminal lobe and in the shape of the pro-




Figure 2 (See legend on next page.)
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Figure 2 MK5 models. A: Final backbone Cα-traces of the MK5 homolog model based on the crystal
structure of MK3 (3FHR). The model predicts an N-terminal lobe consisting of a bundle of β-sheets and a
conserved α-helix. The C-terminal lobe is largely helical and contains a segment, the activation segment, which
includes Thr182 that becomes phosphorylated when MK5 is activated. The hinge region connects the two
lobes, and this is where the ATP binding site is predicted to reside. Color coding: Purple via blue, green and
yellow to red from N-terminal to C-terminal. B: Final backbone Cα-traces of the MK5 homolog model based on
the crystal structure of MK2 (3M2W). Color coding as Figure 2A. C: Final backbone Cα-traces of the MK5
homolog model based on the crystal structure of MK2 (2OZA). Color coding as Figure 2A.
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the crystal structure 2OZA is in the apo- (unbound) form, whilst the other two
templates have a ligand bound in the ATP pocket. Figure 3 shows the ATP binding sites
of the superimposed models. The position of the P-loop was different in the three models.
In the 2OZA-based model the gap between Ile32 in the middle of the P-loop and the
Asp169 of the DFG motif was 8.68Å. The same distance in the 3M2W- and 3FHR-based
MK5 models respectively were of 8.55Å and 6.89Å.
The Ramachandran plot retrieved through ProCheck showed that all models pos-
sessed more than 90% of the amino acids in core regions, 9% in allowed regions, and
approximately 1% in generously allowed regions. None of the amino acids were in
disallowed regions. All models had an Errat option above 85, and together with the
ProCheck results, this indicates that the models were of decent stereochemical quality.
WhatCheck confirmed that the models are of satisfactory quality. Interestingly, after
removal of the flexible loop of the C-terminal lobe, the results given by the SAVSFigure 3 ATP binding site of superimposed models. Color coding: 3FHR-based MK5 model: pink;
3M2W-based MK5 model: green; 2OZA-based MK5 model: blue. Important structural parts are marked out
with text for easier orientation within the model.
A
B
Figure 4 ATP binding site. A: Proposed ATP binding site of the 3FHR-based MK5 model. B: Ligand 92
docked in proposed ATP binding site of the MK5 model after 50 ns of MD. Color coding: Backbone
Cα-traces: Purple via blue, green and yellow to red from N-terminal to C-terminal; Amino acids important
for binding of ligand colored according to atom type (C = grey; H = dark grey; O = red; N = blue); Ligand
92: colored according to atom type (C = yellow; H = dark grey; O = red; N = blue). Hydrogen bonds are
displayed as dotted lines.
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giving Errat values >90. This indicates that these models were of high quality except
for the large flexible loop in the activation segment.
In order to identify structural differences between the models and their templates,
the different 3D models were superimposed onto their corresponding template and
the RMSD between backbone Cα- atoms were calculated. This was done by the use
of DaliLite. The 2OZA-based model has a 46% sequence identity with the template
structure 2OZA and an RMSD value of 0.9Å, while the 3M2W-based model has a
sequence identity of 46% and an RMSD of 0.8Å. The 3FHR-based model displays a
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of 0.7Å. Most of the differences between the models and their templates are seen in
the flexible loop structures of the activation segment in the C-terminal lobe. Both
results obtained from the SAVS Metaserver and DaliLite indicate that the models
based on 3FHR and 3M2W are the stereochemically best models.
In order to evaluate the models’ ability to distinguish between real inhibitors and
decoy substances, the three different models were docked both with the 90 decoy
ligands and 10 inhibitors in a semi-flexible mode. Score values from the different
dockings ranged from +6 to −36, depending on the model used and the ligand (see
Additional files 2, 3, 4 for full list). Figure 4A shows the proposed ATP binding site
of the 3FHR-based MK5 model according to ICM Pocket Finder. Common for all of
the models was that strong inhibitors had a score value better than −31 and important
amino acids for binding of ligands were Lys51, Met105 and Asp169 in the predicted
ATP binding site. Ligand 92 had a score value of −36. This compound is predicted to
bind closely to the previously mentioned amino acids via hydrogen bonds. Ligand 92
was positioned in the ATP binding cleft between the N- and C-terminal lobes of
MK5. It is planar and boomerang shaped with a flexible end, mimicking ATP binding
with the pyrimidine ring occupying the same position as seen for the adenine moiety
of ATP in MK2 [PDB: 1NY3]. A partial stable hydrogen bond to the backbone amide
of Met 105 in the hinge region via the nitrogen of the pyrimidine ring was formed. In
addition, the ligand formed a limited number of hydrogen bonds to the active site
residues of MK5. The oxygen of the pyrrole-pyrimidin ring interacted with the ε-
amino group of Lys 51 (1.88Å), and the nitrogen (N5) of the the pyrrole-pyrimidin
ring interacted with the carboxyl group of Asp 169 (1.51Å). The active site residues
themselves also formed a number of hydrogen bonds contributing to keeping the
complex stable. Lys51 formed a hydrogen bond with the carboxyl group of both Asp
169 (1.72Å) and Glu62 (1.6Å), while Glu62 formed an additional hydrogen bond with
the nitrogen of Gly71 (1.68Å). The gatekeeper residue Met102 of MK5 did not seem
to make contact with Ligand 92. Ligand 92 in the binding site of the 3FHR model
after 50 ns of MD is shown in Figure 4B.
The Lysine residue 51 is positioned at the back wall of the ATP-binding niche and is
highly conserved amongst mammalian protein kinases. It is believed to be involved in
the orientation of the α- and β-phosphate groups of ATP [57]. Mutation of Lys51 to
Methionine or Glutamic acid in the ATP pocket of MK5 completely removed the
kinase activity [8,9]. Consistent with this we observed that many of the known inhibitors
bound to Lys51 in the model or blocked the access of ATP to Lys51.
Comparing the 3FHR- and 3M2W-based models with the active ADP bound crystal
structure of MK2 [PDB: 1NY3], revealed that the models appeared to have adopted
an active kinase conformation [58], with the catalytic residues Lys51 and Glu62 close
enough to make ion pair interaction, and Asp169 in DFG-in conformation, the same
conformation as that seen in the active MK2/ADP structure [PDB: 1NY3]. In that
conformation the catalytic residues can interact with ATP for phosphate transfer.
ADP was docked into the ATP binding sites of the 3FHR- and 3M2W-based models,
and it appears that since the 3FHR- and 3M2W-based models originated from complexes
with inhibitors, the ATP-binding site was too narrow to accommodate ADP. This was




Figure 5 ROC curves created from the score values. A: 3FHR-based model. B: 2OZA-based model.
C: 3M2W-based model.
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ADP was slightly wider. The distance between the carboxyl group of Asp169 and
Gly31 in the glycine-rich loop in the 3FHR-based model was 5.3Å. In contrast, dis-
tance between the carboxyl group of Asp207 and Gly73 in the glycine-rich loop in
the MK2 crystal structure [PDB: 1NY3] complexed with ADP was 8.63Å. ADP
yielded the same orientation as ADP in the MK2 [PDB: 1NY3] complex, but it was
localized approximately 1Å further out from the binding site. The narrowing of the
ATP binding site induced by a ligand has also been shown in the crystal structure of
MK3 [PDB: 3FHR] complexed with the high-affinity pharmaceutical lead compound
(2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one) (P4O)
[56]. In this crystal structure complex, the flexible glycine-rich loop in the binding
site occupies the position of the β-phosphate of ADP, thus binding of P4O induces a
conformation of a deep and narrow ATP binding pocket in MK3.
The docking results were evaluated both by score values and ROC curves, which
describes the tradeoff between “specificity” and “sensitivity”. “Specificity” is the ability
to avoid false positives, and “sensitivity” is the ability of the classifier to detect trueA
B
Figure 7 Plots of atomic distance variations. A: Plot of the atomic distance variation of the hydrogen
bonds between the Asp169 carboxyl group oxygen atoms and Ligand 92 during the 50 ns of MD simulation.




Figure 8 EPS of ATP binding sites. A: EPS of the ATP binding site of the 3FHR-based MK5 model. B: EPS
of the ATP binding site of the 3FHR MK3 crystal structure. C: EPS of the ATP binding site of the 3M2W MK2
crystal structure. Color coding: negative (−5 kcal/mol) red, via white, to positive (+5 kcal/mol): blue.
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while the ROC value of a random classifier is 0.5, the ROC value of an excellent classifier
is greater than 0.9 [59]. The 3FHR-based model gives a near ideal ROC curve, with
an area under the curve calculated to be 0.88, indicating this model performs very
well for predicting ligand binding to the ATP site (Figure 5A). The 2OZA- and
3M2W-based models (Figure 5B and C), however, give a graph close to the diagonal
line (with an area under curve calculated to 0.67), indicating that these models gave a
somewhat random result and are less suited for predicting ligand binding than the
3FHR-based model.
Both 3FHR and 2M2W are crystal structures of kinases with a ligand in the ATP
binding site. 2OZA on the other hand is in apo- (unbound) form bound to the
upstream kinase p38. The models built reflect this difference in template by having a
much narrower ATP binding pocket for the 2OZA-based model than the others.
Figure 9 Comparison of ATP binding sites of MK5 model, and MK2 (3M2W) and MK3 (3FHR) crystal
structures. Important amino acids for ligand interaction are labeled at tip of residues. Constructed model
based on 3FHR is colored red, 3M2W crystal structure is colored blue and 3FHR crystal structure is
colored green.
Table 2 Result from comparison of ATP binding site of MK2, MK3 and MK5
MK5 model MK2_2OZA (fastafile) MK2_3M2W (fastafile) MK3_3FHR (fastafile)
Q26 Q68 Q68 Q48
L28 L70 L70 L50
G29 G71 G71 G51
A30 L72 L72 L52
G31 G73 G73 G53
I32 I74 I74 V54
V36 V78 V78 V58
R47 K89 K89 K69
A49 A91 A91 A71
K51* [8,9] K93 K93 K73
E62* E104 E104 E84
V76 V118 V118 V98
M102** M138 M138 M118
E103 E139 E139 E119
M104 C140 C140 C120
M105 L141 L141 M121
E106 D142 D142 E122
G107 G143 G143 G123
G108 G144 G144 G124
E152 E190 E190 E170
N153 N191 N191 N171
L155 L193 L193 L172
C168 T206 T206 T186
D169* D207 D207 D187
* Amino acid important for binding of ATP [58].
** Gate keeper residue.
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http://www.tbiomed.com/content/10/1/562OZA is in apo- (unbound) form, which probably explains why 2OZA is an unsuitable
template for constructing an active MK5 model that can be used to identify chemical
probes that bind the ATP pocket. This was also obvious when docking known inhibitors
into this model. The pocket is too narrow, and poor scoring values were obtained.
The ROC curves also indicate that the model was not able to distinguish between
known inhibitors and decoys. However, the 2OZA model may be suitable for identifi-
cation of possible type II kinase inhibitors that typically bind to kinases in the inactive
state [60].
Figure 6 shows the graph of the RMSD of the backbone of the 3FHR-based MK5
model in complex with Ligand 92 during the 50 ns of MD simulation. The average
3FHR-based MK5 model during the last 21.3 ns of MD simulation was superimposed
onto the initial 3FHR-based MK5 model, and the RMSD value was 0.803, indicating a
very stable MK5-ligand complex. Figure 7A shows a plot of the atomic distance variation
of the hydrogen bonds between the Asp169 carboxyl group oxygen atoms and Ligand
92 during the 50 ns of MD simulation, and Figure 7B shows a plot of the atomic distance
variation of the hydrogen bonds between the Lys51 amino group and Ligand 92. The
plot indicates that hydrogen atom 1 and 3 exchanges places as participants in the
hydrogen bond between the Lys51 amino group and Ligand 92 during the simulation.
The Ramachandran plot of the average structure is shown as an additional figure
(Additional file 5). A video of the 50 ns of MD simulation of the 3FHR-based MK5
model in complex with Ligand 92 (Additional file 6) indicates that the complex is
generally stable. Observable dynamic flexibility of the binary complex (from video)
also features that from 22 ns to 50 ns, the terminal sequence Met340 – Ser348 is turning
inward to the active site direction, and from 20 ns to 50 ns the loop between Gln87
and Pro94 is turning downwards towards the active site. From 22 ns to 50 ns, the
helix-loop-helix stretch between Ala191 and Lys205 appears to be flexible, and from
0 ns to 50 ns, the longest loop, between Gly237 and Ser274 is very flexible.
The main challenge in developing new chemical probes towards protein kinases is
selectivity of the probes in order to discriminate between the different protein kinases.
At the moment no selective MK5 inhibitors are known, and the selected inhibitors in
the present docking study are also able to inhibit MK2 and MK3. This, however, is
not important at the present stage since the model is only meant to be able to identify
binders versus non binders. The present 3FHR-based MK5 model can be used to elucidate
the uniqueness of the MK5 ATP-binding site and may serve as a working tool for de-
veloping chemical probes using interactive drug design. Figures 8A, B and C show
the EPS of the ATP binding sites of the 3FHR-based MK5 model, the 3FHR MK3
crystal structure and the 3M2W MK2 crystal structure. The EPS of the ATP binding site
of the 3FHR-based MK5 model appears to be electronegative in its two deeper cavities
and electropositive in its outer areas. The EPS of the ATP binding site of the 3FHR MK3
crystal structure is entirely electronegative, and the EPS of the ATP binding site of the
3M2W MK2 crystal structure is partly electropositive and partly electronegative. The sizes
of the cavities of the 3FHR-based MK5 model, the 3FHR MK3 crystal structure and the
3M2W MK2 crystal structure, measured using ICM Pocket Finder, were 420Å3, 384Å3
and 331Å3, respectively. Amino acids Asp169, Lys51 and Glu62 (numbers related to
MK5), which are important for the binding and phosphate transfer from ATP [58],
are located in the similar positions in all three kinases. There are, however, some
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ing position, MK2 and MK3 both have a threonine. A cysteine in the ATP binding site
may represent a unique opportunity for the construction of irreversible covalent in-
hibitors to the nucleophilic cysteine residue [61]. Development of irreversible inhibi-
tors that form covalent bonds with cysteine in the ATP-binding pocket is currently
gaining interest [62]. Irreversible kinase inhibitors may have potential advantages in-
cluding prolonged pharmacodynamics and suitability for rational drug design. Other
amino acids in the ATP binding site of MK5 that are different from the corresponding po-
sitions in both MK2 and MK3 are Ala30 (leucine in MK2 and MK3), Arg47 (lysine in
MK2 and MK3), and Met104 (cysteine in MK2 and MK3) (Table 2).Conclusions
Even though the biological function of MK5 still remains elusive, it will be interesting
to see how its role as a possible drug target may be elucidated in the near future. The
3FHR-based model presented in this study was effective in discrimination between
known inhibitors and decoys, being capable of discriminating between 10 actives and
90 property-matched decoys at 88% level. This indicates that this model may be used
as a working tool for further experimental studies and possibly structure aided drug
design. Given the tumor suppressor and tumor promoting properties of active MK5
(reviewed in Kostenko et al. [63]), the design of specific MK5 activators and inhibitors
may have important therapeutic potentials.
Coordinates of MK5 models and protein-ligand complexes are available upon request.
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